Abstract
The National Institutes of Health (NIH), academic medical centers and industry have a long and productive history in collaborating together. Decreasing R&D budgets in both the private and public sector have made the need for such collaborations paramount to reduce the risk of further declines in the number of innovative drugs reaching the market to address pressing public health needs. Doing more with less has forced both industry and public sector research institutions (PSRIs) to leverage resources and expertise in order to de-risk projects. In addition, it provides an opportunity to envision and implement new approaches to accomplish these goals. We discuss several of these innovative collaborations and partnerships at the NIH that demonstrate how the NIH and industry are working together to strengthen the drug development pipeline.
Keywords: Collaboration, de-risking, drug repurposing, drug rescue, public private partnerships, technology transfer, translational.
Current Topics in Medicinal Chemistry
Title:Leveraging Public Private Partnerships to Innovate under Challenging Budget Times
Volume: 14 Issue: 3
Author(s): Lili M. Portilla and Mark L. Rohrbaugh
Affiliation:
Keywords: Collaboration, de-risking, drug repurposing, drug rescue, public private partnerships, technology transfer, translational.
Abstract: The National Institutes of Health (NIH), academic medical centers and industry have a long and productive history in collaborating together. Decreasing R&D budgets in both the private and public sector have made the need for such collaborations paramount to reduce the risk of further declines in the number of innovative drugs reaching the market to address pressing public health needs. Doing more with less has forced both industry and public sector research institutions (PSRIs) to leverage resources and expertise in order to de-risk projects. In addition, it provides an opportunity to envision and implement new approaches to accomplish these goals. We discuss several of these innovative collaborations and partnerships at the NIH that demonstrate how the NIH and industry are working together to strengthen the drug development pipeline.
Export Options
About this article
Cite this article as:
Portilla M. Lili and Rohrbaugh L. Mark, Leveraging Public Private Partnerships to Innovate under Challenging Budget Times, Current Topics in Medicinal Chemistry 2014; 14 (3) . https://dx.doi.org/10.2174/1568026613666131127155703
DOI https://dx.doi.org/10.2174/1568026613666131127155703 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Coagulation and Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Allopurinol and Loss of Consciousness in a 78-old Year Man Suffering from Gout
Infectious Disorders - Drug Targets Nanobiotechnology-based Drug Delivery in Brain Targeting
Current Pharmaceutical Biotechnology The Kdo Biosynthetic Pathway Toward OM Biogenesis as Target in Antibacterial Drug Design and Development
Current Drug Discovery Technologies Convection Enhanced Drug Delivery of Novel Therapeutic Agents to Malignant Brain Tumors
Current Drug Delivery Overview of Brain Tumor Stem Cells – Implications for Treatment
Current Signal Transduction Therapy Inflammatory Mediators as Potential Therapeutic Targets in the Spine
Current Drug Targets - Inflammation & Allergy Neurological Involvement in Rheumatoid Arthritis
Current Immunology Reviews (Discontinued) A RP-HPLC-UV Method with Solid Phase Extraction for Determination of Cefepime in Total Nutrient Admixtures: Application to Stability Studies
Current Pharmaceutical Analysis Colorectal Carcinogensis and Suppression of Tumor Development by Inhibition of Enzymes and Molecular Targets
Current Enzyme Inhibition Cell Adhesion Molecules in Gene and Cell Therapy Approaches for Nervous System Repair
Current Gene Therapy Pharmacogenomics and Severe Infections: The Role of the Genomes of Both the Host and the Pathogen
Current Pharmacogenomics Tumor-Associated Macrophages as Potential Targets for Anti-Cancer Activity of Marine Invertebrate-Derived Compounds
Current Pharmaceutical Design Drug Targets of Migraine and Neuropathy: Treatment of Hyperexcitability
CNS & Neurological Disorders - Drug Targets The Molecular Genetics of Migraine: Toward the Identification of Responsible Genes
Current Genomics Selective Sensitization to Penicillin V with Tolerance to Other Betalactams
Recent Patents on Inflammation & Allergy Drug Discovery Antibodies: Can They Protect Against HIV Infection?
Current Drug Targets - Infectious Disorders Natural Compounds Therapeutic Features in Brain Disorders by Experimental, Bioinformatics and Cheminformatics Methods
Current Medicinal Chemistry Update on Diagnostic and Treatment of Uncomplicated and Complicated Malaria in Adults and Selected Vulnerable Populations
Infectious Disorders - Drug Targets Pyrimethamine as a Potent and Selective Inhibitor of Acute Myeloid Leukemia Identified by High-throughput Drug Screening
Current Cancer Drug Targets